The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Generating Stronger And Smarter T Cells For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$310,332.00
Summary
White blood cells from cancer patients can be modified in the laboratory to react against tumours. These cells can then be given back to the patient, which can sometimes cause cancer regression. However, often the white blood cells lack strength, or they lack the ability to distinguish between tumour and normal tissues of the body. In this project we seek to make stronger and smarter white blood cells that can deliver a lethal hit against tumours without damaging essential organs of the body.
microRNAs and the control of T lymphocyte differentiation, function and malignant transformation. The molecular mechanism of the immune system is not completely understood. This project will investigate how transcription factors and microRNAs, two major types of regulatory molecules work together to control immune responses. The results from this research will assist in the design of better vaccination strategies and treat certain lymphomas.
Discovery Early Career Researcher Award - Grant ID: DE180100484
Funder
Australian Research Council
Funding Amount
$365,058.00
Summary
Tipping the balance from tolerance to immunity for the devil facial tumour. This project aims to develop a single-shot vaccine for the Tasmanian devil facial tumour disease. The disease is an enigma because the transmissible tumours are simultaneously cancer, infections, and genetically mismatched tissue grafts. This project will focus on immune molecules that are revolutionising human oncology, and will develop techniques to understand and systematically test the function of these key molecules ....Tipping the balance from tolerance to immunity for the devil facial tumour. This project aims to develop a single-shot vaccine for the Tasmanian devil facial tumour disease. The disease is an enigma because the transmissible tumours are simultaneously cancer, infections, and genetically mismatched tissue grafts. This project will focus on immune molecules that are revolutionising human oncology, and will develop techniques to understand and systematically test the function of these key molecules in Tasmanian devils. Understanding the role of these immune molecules will accelerate development of a vaccine to help save the devil and has the potential to shed light on general principles relating to how the immune system balances tolerance and immunity.Read moreRead less
Immunisation to protect against transmissible cancers in Tasmanian devils. This project aims to identify the immune escape mechanisms that the transmissible cancers, Devil Facial Tumour Disease (DFTD) use to avoid being killed by the immune system. Since the discovery of the second transmissible cancer (DFT2) mystery surrounds whether the devils immune system can respond to this cancer, hence this project will investigate the immune response to DFT2. The final aims are to develop a vaccine with ....Immunisation to protect against transmissible cancers in Tasmanian devils. This project aims to identify the immune escape mechanisms that the transmissible cancers, Devil Facial Tumour Disease (DFTD) use to avoid being killed by the immune system. Since the discovery of the second transmissible cancer (DFT2) mystery surrounds whether the devils immune system can respond to this cancer, hence this project will investigate the immune response to DFT2. The final aims are to develop a vaccine with the potential to protect healthy devils and cure devils with DFTD.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE110100106
Funder
Australian Research Council
Funding Amount
$350,000.00
Summary
An advanced flow cytometry facility for the Peter Doherty Institute. The establishment of a flow cytometry facility in the new Peter Doherty Institute for Infection and Immunity will enhance capacity to investigate immunity to a broad range of very serious diseases. This project will support researchers studying viral and bacterial infection as well as cancer and autoimmunity.
Host-tumour interplay in Tasmanian devils with devil facial tumour disease: can immune cells be harnessed for therapy? Tasmanian devils only exist naturally in Tasmania and Devil Facial Tumour Disease, an infectious cancer, could cause the extinction of the Tasmanian devil. This project will determine if Devil Facial Tumour Disease reduces the effectiveness of the devil's immune system and test if activated immune cells can protect against this disease.
Real-time analysis of tumour-infiltrating T cells using novel analytical tools. By dynamic visualization of immune cells within intact tumours, we have shown that active screening for target cells optimises their anti-tumour effect. This project will develop novel mathematical/analytical tools to unravel the basic strategies that enable immune cells to position themselves at the right location at the right time.
Adenosine Receptor Antagonists As Immunotherapeutic Agents For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$555,779.00
Summary
We have shown that drugs that block immunosuppressive adenosine receptors can improve anti-tumour immune responses and consequently enhance the effectiveness of chemotherapy. These drugs are already known to be well-tolerated in humans and so have great potential for clinical development. We propose to determine the therapeutic response achieved with these drugs in combination with established cancer treatments involving radiotherapy and immune based therapies.
Investigating The Anti-tumour Efficacy And On Target Toxicity Of Gene-modified T Cell Therapy In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$337,614.00
Summary
White blood cells from cancer patients can be modified in the laboratory to react against tumours. Although these cells can induce cancer regression when given back to the patient, these cells can often cause associated pathology. In this study we propose to fully investigate the limits of this type of therapy for mediating anti-tumour responses and potential toxicity in mouse models that closely recapitulate the human setting. These studies will lead to a more effective therapy for patients.
Utilization Of Gene-engineered T Cells For Enhancing Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$761,656.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.